Abstract Number: 0285 • ACR Convergence 2025
Delayed-Onset Myopathy in Dermatomyositis: A Retrospective Cohort Study
Background/Purpose: Amyopathic dermatomyositis (ADM) is a subset of DM in which cutaneous findings occur without muscle disease for >6 months after diagnosis. However, there is…Abstract Number: 1912 • ACR Convergence 2025
Cutaneous manifestations of vasculitis: A cross-sectional analysis from an international cohort
Background/Purpose: Vasculitis is a group of rare, multisystem diseases which may involve the skin. Characterization of the frequency, type, and significance of cutaneous manifestations in…Abstract Number: 0278 • ACR Convergence 2025
Classic and Clinically Amyopathic Dermatomyositis: Autoantibody Positivity
Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy subclassified as classic (CDM) and clinically amyopathic (CADM). It can involve myositis-associated (MAA) and myositis-specific (MSA) autoantibodies.…Abstract Number: 1898 • ACR Convergence 2025
Assessing Representation in a Nation-Wide Psoriasis Registry: A Single-Institution Comparison
Background/Purpose: Ensuring that data registries include a representative sample is crucial for obtaining findings that can be generalized to the larger population. This comparative observational…Abstract Number: 0277 • ACR Convergence 2025
A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a chimeric degradation activating compound (CDAC), in Healthy Participants
Background/Purpose: Interleukin 1 receptor associated kinase 4 (IRAK4) degradation may modulate toll-like receptor signaling and alleviate symptoms in rheumatoid arthritis and atopic dermatitis.1,2 BGB-45035, an…Abstract Number: 1464 • ACR Convergence 2025
Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
Background/Purpose: Patients with psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are at increased risk of major adverse cardiovascular events (MACE) due to systemic…Abstract Number: 0223 • ACR Convergence 2025
Timely Dermatologic Diagnosis and Management Changes in Systemic Collagen Vascular Diseases: Experiences from the Rheumatology-Dermatology Combined Clinic
Background/Purpose: Collagen vascular diseases (CVD) often present with skin manifestations, but it is not always clear whether these changes are directly related to the underlying…Abstract Number: 1448 • ACR Convergence 2025
Influence of Sex on the Therapeutic Persistence of Guselkumab in Psoriatic Disease: a Retrospective National Cohort Study
Background/Purpose: Psoriatic disease, including psoriasis (Pso) and psoriatic arthritis (PsA), seems to affect male and female patients differently in clinical presentation, disease progression and advanced…Abstract Number: 1166 • ACR Convergence 2025
Biomarkers Associated with Left Atrial Structure and Function in Individuals with Psoriasis
Background/Purpose: Individuals with psoriasis are at increased risk of developing heart disease. Echocardiographic parameters of impaired left atrial (LA) strain (Peak atrial contraction and longitudinal…Abstract Number: 1152 • ACR Convergence 2025
Cutaneous Panniculitis in Rheumatology: A Descriptive Cohort Study from a Multidisciplinary Experience
Background/Purpose: Panniculitis refers to inflammatory disorders of subcutaneous fat that pose diagnostic challenges due to nonspecific clinical features and overlapping histopathological patterns. Although it can…Abstract Number: 0998 • ACR Convergence 2025
Preclinical Characterization of a Novel Bi-specific Antibody Targeting IL-23p19 and IL-36R for The Treatment of Autoimmune Diseases
Background/Purpose: IL-23 is a pivotal cytokine driving IL-17-mediated inflammation, and its inhibition has shown efficacy in Th17-associated autoimmune diseases. However, patient heterogeneity and compensatory pathways…Abstract Number: 2699 • ACR Convergence 2025
Cutaneous IgA Vasculitis: Emulation of a Target Trial from a European Multicentric Retrospective Study
Background/Purpose: Immunoglobulin A vasculitis (IgAV) is a small vessel vasculitis marked by IgA, deposition, palpable purpura with lower body predilection and variable joints, kidney and…Abstract Number: 0926 • ACR Convergence 2025
Discovery and Characterization of SIM0711: a Potent and Selective IRAK4 PROTAC with Improved Efficacy and Safety
Background/Purpose: IRAK4 plays a pivotal role in the innate immune response by acting downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R), with both…Abstract Number: 0930 • ACR Convergence 2024
The Common Form of the Inflammatory Skin Disease Hidradenitis Suppurativa Is Associated with Low Nicastrin Expression in Dermal Fibroblasts
Background/Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses in intertriginous areas. Despite its increasing prevalence, the etiology…Abstract Number: 0988 • ACR Convergence 2024
Antinuclear Antibody Positivity and Its Diagnostic Implications for Rheumatic Diseases in Dermatology Patients: A Comprehensive Single Center Analysis
Background/Purpose: Cutaneous manifestations are common in rheumatic diseases and can be early indicators. This study investigates the prevalence of rheumatic diseases diagnosed through ANA (Antinuclear…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 8
- Next Page »
